Tufts Center for the Study of Drug Development (CSDD) released an analysis suggesting an agentic AI clinical monitoring system can materially improve oncology trial economics. The report modeled Medable’s Clinical Monitoring Agent and estimated expected net present value (eNPV) gains of up to $21 million for phase III development, alongside ROI estimates as high as 82x. Tufts tied the financial impact to operational changes such as fewer on-site monitoring visits, reduced travel costs, faster enrollment timelines, and earlier database lock dates. It also estimated direct operating cost reductions of about $4.4 million in phase II and $5.6 million in phase III per trial. The analysis further concluded that agentic AI could accelerate clinical development by roughly 10 weeks, compressing administrative timelines in addition to improving enrollment pacing. While the findings are based on benchmarked and contract value datasets rather than a head-to-head clinical outcome study, they provide quantification that could influence how sponsors budget and deploy AI tools in trials.